Development of therapeutic antibodies for the treatment of diseases

Abstract

It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years. Over the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, and in 2018, eight of the top ten bestselling drugs worldwide were biologics. The global therapeutic monoclonal antibody market was valued at approximately US$115.2 billion in 2018 and is expected to generate revenue of $150 billion by the end of 2019 and $300 billion by 2025. Thus, the market for therapeutic antibody drugs has experienced explosive growth as new drugs have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. As of December 2019, 79 therapeutic mAbs have been approved by the US FDA, but there is still significant growth potential. This review summarizes the latest market trends and outlines the preeminent antibody engineering technologies used in the development of therapeutic antibody drugs, such as humanization of monoclonal antibodies, phage display, the human antibody mouse, single B cell antibody technology, and affinity maturation. Finally, future applications and perspectives are also discussed.

Cited by papers we hold 25

• Development and Validation of the Cell-based Functional Method for Neutralizing Anti-adalimumab Antibodies Detection in Human Serum · 2024
  Not checked
• Exploring treatment options in cancer: tumor treatment strategies · 2024
  No notice
• Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies · 2024
  No notice
• Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy · 2024
  No notice
• Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system · 2023
  No notice
• Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases · 2023
  No notice
• The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress · 2023
  No notice
• ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins · 2023
  No notice
• A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
  No notice
• Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis · 2022
  Not checked
• Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life · 2022
  Not checked
• Donepezil ameliorates Aβ pathology but not tau pathology in 5xFAD mice · 2022
  Not checked
• Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s · 2022
  Not checked
• Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate · 2022
  No notice
• In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications · 2022
  No notice
• The Antibody Registry: ten years of registering antibodies · 2022
  No notice
• Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space · 2022
  No notice
• Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment · 2022
  No notice
• SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants · 2021
  No notice
• Functional Characterization of Pembrolizumab Produced in Nicotiana benthamiana Using a Rapid Transient Expression System · 2021
  Not checked

and 5 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.